Trulicity (dulaglutide) is a weekly GLP-1 receptor agonist FDA-approved for type 2 diabetes, not primarily for weight loss. Standard doses are 0.75 mg (starter), 1.5 mg (typical maintenance), 3.0 mg, and 4.5 mg (maximum). Off-label use for weight loss produces modest results — typically 3 to 6 percent weight loss at the 1.5 mg dose and 5 to 7 percent at 4.5 mg over 6 to 12 months. This is meaningfully less than Wegovy (~15 percent at 2.4 mg) or Zepbound (~20 percent at 15 mg). Insurance coverage for weight loss alone is poor; Trulicity is best considered when type 2 diabetes is the primary indication.
The Dose Ladder
| Dose | Purpose | Typical Duration | Typical A1C Drop | Typical Weight Loss |
|---|---|---|---|---|
| 0.75 mg weekly | Starter | 4 weeks | −0.7 to −0.9 | 1–2% |
| 1.5 mg weekly | Common maintenance | Long term | −1.0 to −1.4 | 2–3% |
| 3.0 mg weekly | Intensification | Long term | −1.4 to −1.7 | 3–5% |
| 4.5 mg weekly | Maximum | Long term | −1.5 to −1.9 | 5–7% |
The Titration Schedule
- Weeks 1–4: 0.75 mg weekly (GI adaptation)
- Weeks 5 onward: 1.5 mg weekly (most common maintenance)
- If A1C or weight-loss goals not met after 4 weeks at 1.5 mg: step up to 3.0 mg
- If still not met after another 4 weeks: step up to 4.5 mg (maximum)
- Each titration step should be held for at least 4 weeks before further increase
How Trulicity Compares With Other GLP-1 Drugs for Weight Loss
| Drug | Max Dose | Typical Weight Loss at Max Dose | FDA Indication for Weight Loss |
|---|---|---|---|
| Trulicity (dulaglutide) | 4.5 mg weekly | 5–7% | No (off-label) |
| Ozempic (semaglutide) | 2 mg weekly | 8–10% | No — T2D only (off-label for weight) |
| Wegovy (semaglutide 2.4 mg) | 2.4 mg weekly | 13–15% | Yes |
| Mounjaro (tirzepatide) | 15 mg weekly | 12–15% | No — T2D only (off-label for weight) |
| Zepbound (tirzepatide) | 15 mg weekly | 15–21% | Yes |
| Saxenda (liraglutide) | 3 mg daily | 5–7% | Yes |
| Victoza (liraglutide) | 1.8 mg daily | 3–5% | No — T2D only |
Why Weight Loss Is More Modest with Trulicity
- Dulaglutide has a slightly different pharmacokinetic profile than semaglutide — shorter half-life and different receptor binding dynamics
- Maximum approved dose of 4.5 mg produces less GLP-1 receptor activation than semaglutide 2.4 mg
- Tirzepatide’s dual GLP-1 + GIP mechanism adds to weight loss beyond GLP-1 alone
- Trulicity’s development was focused on A1C control in type 2 diabetes, not weight loss optimization
When Trulicity Is the Right Choice
- Type 2 diabetes with A1C goal as the primary target
- Insurance formulary preferring Trulicity over Ozempic or Mounjaro
- History of severe GI side effects on semaglutide (some patients tolerate dulaglutide better)
- Preference for a simpler pen device (Trulicity is preset — no dose dialing)
- Prior success on Trulicity without desire to switch
When Trulicity Is Not the Best Choice
- Primary goal is weight loss (Wegovy, Zepbound, or Saxenda are better)
- BMI ≥ 30 without type 2 diabetes — insurance unlikely to cover off-label
- Needing significant weight loss (more than 10 percent of body weight)
- Unable to tolerate GI side effects even at 0.75 mg (switch to lower-starting option)
Side Effect Profile
- Nausea: 10–20% (usually transient; worst during titration)
- Diarrhea: 10–15%
- Vomiting: 5–10%
- Constipation: 5–10%
- Abdominal pain: 5–10%
- Decreased appetite: 5–10%
- Injection-site reactions: 2–5%
- Rare serious: pancreatitis, gallbladder disease, medullary thyroid C-cell tumors (black-box warning based on rodent data)
- Hypoglycemia: rare as monotherapy; increased when combined with insulin or sulfonylureas
Pen and Injection Technique
- Single-use pen; preset dose
- No dose dialing — press the button, wait for the audible click, count to 10
- Inject subcutaneously in abdomen, thigh, or back of upper arm
- Rotate sites to avoid lipohypertrophy
- Can take at any time of day; same day each week
- Can switch injection days by up to 3 days if needed
- Store unopened in refrigerator; in-use pen good at room temp for 14 days
Cost and Access
- Retail cash: ~$900 per month
- Commercial insurance + Trulicity Savings Card: $25 per month for eligible patients
- Medicare Part D: covered for T2D
- Lilly patient assistance: available for uninsured and low-income
- For weight loss alone, coverage is typically denied — switch to branded weight-loss indications (Wegovy, Zepbound, Saxenda) often has better access
What to Expect in the First 3 Months
- Week 1–2: mild nausea and appetite reduction; minimal weight change
- Week 3–4: side effects improving; smaller meals feel natural; 1 to 3 pounds down
- Week 5–8: on 1.5 mg; 2 to 5 pounds down cumulative
- Week 9–12: stabilizing; 4 to 8 pounds down; A1C dropping 0.5 to 1.0 percentage points
- Month 6: 8 to 15 pounds down in most patients
- Month 12: 10 to 20 pounds down; plateau typically beginning
Transition Options If Trulicity Is Not Enough
- Step up to 3.0 mg or 4.5 mg (if not already at maximum)
- Switch to semaglutide (Ozempic or Wegovy) — typically an additional 5 to 8 percent weight loss
- Switch to tirzepatide (Mounjaro or Zepbound) — typically an additional 10 to 15 percent weight loss
- Add SGLT2 inhibitor for additional A1C reduction and cardio-renal benefit
- Consider metabolic surgery if BMI ≥ 35 and medication has not met goals
Related Reading
See our guides on treatment options and reversibility.
The Bottom Line
Trulicity is FDA-approved for type 2 diabetes, not weight loss. Off-label weight-loss use produces 3 to 6 percent loss at standard 1.5 mg dosing and 5 to 7 percent at the maximum 4.5 mg dose. This is less than semaglutide or tirzepatide. Insurance coverage for weight loss alone is limited. Trulicity is a reasonable choice when type 2 diabetes is the primary indication, when insurance prefers it over other GLP-1s, or when GI tolerance to semaglutide is poor. For patients whose primary goal is significant weight loss, Wegovy or Zepbound (FDA-indicated for weight loss) are usually better choices.
